Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Röllig, Christoph, Dr, Serve, Hubert, Prof, Hüttmann, Andreas, MD, Noppeney, Richard, MD, Müller-Tidow, Carsten, Prof, Krug, Utz, MD, Baldus, Claudia D, Prof, Brandts, Christian H, MD, Kunzmann, Volker, Prof, Einsele, Hermann, Prof, Krämer, Alwin, Prof, Schäfer-Eckart, Kerstin, MD, Neubauer, Andreas, Prof, Burchert, Andreas, Prof, Giagounidis, Aristoteles, MD, Krause, Stefan W, Prof, Mackensen, Andreas, Prof, Aulitzky, Walter, Prof, Herbst, Regina, MD, Hänel, Mathias, MD, Kiani, Alexander, Prof, Frickhofen, Norbert, Prof, Kullmer, Johannes, MD, Kaiser, Ulrich, Prof, Link, Hartmut, Prof, Geer, Thomas, MD, Reichle, Albert, Prof, Junghanß, Christian, Prof, Repp, Roland, Prof, Heits, Frank, MD, Dürk, Heinz, Prof, Hase, Jana, Klut, Ina-Maria, PhD, Illmer, Thomas, MD, Bornhäuser, Martin, Prof, Schaich, Markus, Prof, Parmentier, Stefani, MD, Görner, Martin, MD, Thiede, Christian, Prof, von Bonin, Malte, MD, Schetelig, Johannes, Prof, Kramer, Michael, MSc, Berdel, Wolfgang E, Prof, Ehninger, Gerhard, Prof
Published in The lancet oncology (01.12.2015)
Published in The lancet oncology (01.12.2015)
Get full text
Journal Article